APA (7th ed.) Citation

Paepke, S., Huober, J., Kümmel, S., Eidtmann, H., Untch, M., Costa, S. D., . . . Minckwitz, G. v. (2016). Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). The European journal of cancer, 57, .

Chicago Style (17th ed.) Citation

Paepke, Stefan, et al. "Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neoadjuvant Treatment in Patients with Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)." The European Journal of Cancer 57 (2016).

MLA (9th ed.) Citation

Paepke, Stefan, et al. "Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neoadjuvant Treatment in Patients with Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)." The European Journal of Cancer, vol. 57, 2016.